Physician profile
Crystal Vann
NPI 1386331700
$3,513.20
in general payments reported to CMS, 2019-2025
19 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.59 · 2022: $12.61 · 2023: $490 · 2024: $498 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.51 |
| Education | $119.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $391.49 | 2023-2024 | Darzalex, Tecvayli, Carvykti |
| Otsuka America Pharmaceutical, INC. | $383.13 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $366.03 | 2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $361.34 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $349.72 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $334.72 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $290.87 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.90 | 2025 | Caplyta |
| Lundbeck LLC | $219.30 | 2024-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $117.19 | 2023 | Keytruda |
| Abbvie INC. | $114.94 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $107.10 | 2025 | Fanapt |
| Gilead Sciences, INC. | $68.48 | 2023 | |
| Janssen Pharmaceuticals, INC | $51.66 | 2025 | Invega Sustenna |
| Bayer Healthcare Pharmaceuticals INC. | $32.21 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.06 | 2025 | Trintellix |
| Lilly USA, LLC | $27.59 | 2021 | |
| Braeburn INC. | $21.60 | 2025 | Brixadi |
| Pharmaessentia USA Corporation | $14.87 | 2023 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Vann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.